Heiser Clemens, Maurer Joachim T, Hofauer Benedikt, Sommer J Ulrich, Seitz Annemarie, Steffen Armin
1 Department of Otorhinolaryngology-Head and Neck Surgery, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
2 Department of Otorhinolaryngology-Head and Neck Surgery, University-Hospital Mannheim, Mannheim, Germany.
Otolaryngol Head Neck Surg. 2017 Feb;156(2):378-384. doi: 10.1177/0194599816683378. Epub 2016 Dec 27.
Objective Selective stimulation of the hypoglossal nerve is a new surgical therapy for obstructive sleep apnea, with proven efficacy in well-designed clinical trials. The aim of the study is to obtain additional safety and efficacy data on the use of selective upper airway stimulation during daily clinical routine. Study Design Prospective single-arm study. Setting Three tertiary hospitals in Germany (Munich, Mannheim, Lübeck). Subjects and Methods A multicenter prospective single-arm study under a common implant and follow-up protocol took place in 3 German centers (Mannheim, Munich, Lübeck). Every patient who received an implant of selective upper airway stimulation was included in this trial (apnea-hypopnea index ≥15/h and ≤65/h and body mass index <35 kg/m). Before and 6 months after surgery, a 2-night home sleep test was performed. Data regarding the safety and efficacy were collected. Results From July 2014 through October 2015, 60 patients were included. Every subject reported improvement in sleep and daytime symptoms. The average usage time of the system was 42.9 ± 11.9 h/wk. The median apnea-hypopnea index was significantly reduced at 6 months from 28.6/h to 8.3/h. No patient required surgical revision of the implanted system. Conclusion Selective upper airway stimulation is a safe and effective therapy for patients with obstructive sleep apnea and represents a powerful option for its surgical treatment.
目的 选择性舌下神经刺激是一种治疗阻塞性睡眠呼吸暂停的新型手术疗法,在精心设计的临床试验中已证实其有效性。本研究的目的是获取在日常临床实践中使用选择性上呼吸道刺激的更多安全性和有效性数据。研究设计 前瞻性单臂研究。地点 德国的三家三级医院(慕尼黑、曼海姆、吕贝克)。研究对象与方法 在德国的3个中心(曼海姆、慕尼黑、吕贝克)按照共同的植入和随访方案进行了一项多中心前瞻性单臂研究。每例接受选择性上呼吸道刺激植入的患者均纳入本试验(呼吸暂停低通气指数≥15次/小时且≤65次/小时,体重指数<35kg/m²)。在手术前和术后6个月,进行了为期2晚的家庭睡眠测试。收集有关安全性和有效性的数据。结果 从2014年7月至2015年10月,共纳入60例患者。每位受试者均报告睡眠和日间症状有所改善。该系统的平均使用时间为42.9±11.9小时/周。呼吸暂停低通气指数中位数在6个月时从28.6次/小时显著降至8.3次/小时。没有患者需要对植入系统进行手术翻修。结论 选择性上呼吸道刺激对阻塞性睡眠呼吸暂停患者是一种安全有效的治疗方法,是其手术治疗的有力选择。